Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

Todd Neale

June 03, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

TCTMD’s Top 10 Most Popular Stories for January 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content